Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Ahmedin Jemal D. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
Shi JF, Qiao YL, Smith JS, Dondog B, Bao YP, Dai M, et al. Epidemiology and prevention of human papillomavirus and cervical cancer in China and Mongolia. Vaccine. 2008;26(Suppl 12):M53–9.
Chen W, Zheng R, Zhang S, Zeng H, Zuo T, Xia C, et al. Cancer incidence and mortality in China in 2013: an analysis based on urbanization level. Chin J Cancer Res. 2017;29(1):1–10.
Zhao FH, Hu SY, Zhang SW, Chen WQ, Qiao YL. Cervical cancer mortality in 2004-2005 and changes during last 30 years in China. Zhonghua Yu Fang Yi Xue Za Zhi. 2010;44(5):408–12.
Bosch FX, Munoz N. The viral etiology of cervical cancer. Virus Res. 2002;89:183–90.
Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC, Zanini RR. Efficacy of human papillomavirus vaccines: a systematic quantitative review. Int J Gynecol Cancer. 2009;19(7):1166–76.
Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila). 2009;2(10):868–78.
China Food and Drug Administration. The license of human papillomavirus bivalent(types 16, 18) vaccine was approved by CFDA. Avariable from: http://www.nmpa.gov.cn/WS04/CL2168/329384.html. Accessed 24 Apr 2019.
The Xinhua News Agency.The license of Human Papillomavirus Quadrivalent(Types6,11, 16, 18) Vaccine was approved by CFDA. Avariable from: http://www.xinhuanet.com/2017-06/20/c_1121179041.htm. Accessed 24 Apr 2019.
Nationl medical products administration. Nine-valant HPV vaccine has been conditionally approvaled for marketing. Avariable from: http://www.nmpa.gov.cn/WS04/CL2094/227881.html. Accessed 18 Jan 2019.
GlaxoSmithKline (China). GSK HPV vaccine has been has been approved as the only HPV vaccine for all women aged 9–45 in mainland China. Avariable from: http://www.gsk-china.com/zh-cn/media/press-releases/2018/gsk-hpv-vaccine-cervarix-is-approved-for-new-vaccination-population-and-has-become-the-only-vaccine-for-cervical-cancer-prevention-in-female-population-aged-9-45-years-in-mainland-china/. Accessed 18 Jan 2019.
Saslow D, Andrews KS, Manassaram-Baptiste D, Loomer L, Lam KE, Fisher-Borne M, et al. American Cancer Society guideline development G: human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement. CA Cancer J Clin. 2016;66(5):375–85.
World Health Organization. Human papillomavirus vaccines: WHO position paper. In: weekly Epidemiology Record, 2017;19(92):241–68. Variable from: https://apps.who.int/iris/bitstream/handle/10665/255353/WER9219.pdf;jsessionid=B3DDE794DAEA6CAD23EA004007EEABBD?sequence=1. Accessed 26 July 2017.
Kwan TT, Tam KF, Lee PW, Chan KK, Ngan HY. The effect of school-based cervical cancer education on perceptions towards human papillomavirus vaccination among Hong Kong Chinese adolescent girls. Patient Educ Couns. 2011;84(1):118–22.
Balla BC, Terebessy A, Toth E, Balazs P. Young Hungarian Students’ knowledge about HPV and their attitude toward HPV vaccination. Vaccines. 2016;5(1). https://doi.org/10.3390/vaccines5010001.
Kwan TT, Chan KK, Yip AM, Tam KF, Cheung AN, Young PM, et al. Barriers and facilitators to human papillomavirus vaccination among Chinese adolescent girls in Hong Kong: a qualitative-quantitative study. Sex Transm Infect. 2008;84(3):227–32.
Li R, Li Y, Radley D, Liu Y, Huang T, Sings HL, et al. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese males and females. Vaccine. 2012;30(28):4284–91.
Roteli-Martins CM, Naud P, De Borba P, Teixeira JC, De Carvalho NS, Zahaf T, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother. 2012;8(3):390–7.
Zhu FC, Chen W, Hu YM, Hong Y, Li J, Zhang X, et al. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial. Int J Cancer. 2014;135(11):2612–22.
Garland SM, Kjaer SK, Munoz N, Block SL, Brown DR, DiNubile MJ, et al. Impact and effectiveness of the Quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016;63(4):519–27.
Wang R, Guo XL, Wisman GB, Schuuring E, Wang WF, Zeng ZY, et al. Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China. BMC Infect Dis. 2015;15:257.
Zhao FH, Tiggelaar SM, Hu SY, Xu LN, Hong Y, Niyazi M, et al. A multi-center survey of age of sexual debut and sexual behavior in Chinese women: suggestions for optimal age of human papillomavirus vaccination in China. Cancer Epidemiol. 2012;36(4):384–90.
Xue L, Hu W, Zhang H, Xie Z, Zhang X, Zhao F, et al. Awareness of and willingness to be vaccinated by human papillomavirus vaccine among junior middle school students in Jinan China. Hum Vaccin Immunother. 2018;14(2):404.
Zhang SK, Pan XF, Wang SM, Yang CX, Gao XH, Wang ZZ, et al. Knowledge of human papillomavirus vaccination and related factors among parents of young adolescents: a nationwide survey in China. Ann Epidemiol. 2015;25:231–5.
Chang IJ, Huang R, He W, Zhang SK, Wang SM, Zhao FH, et al. Effect of an educational intervention on HPV knowledge and vaccine attitudes among urban employed women and female undergraduate students in China: a cross-sectional study. BMC Public Health. 2013;13:916.
Li J, Li LK, Ma JF, Li HW, Niyazi M, Li CQ, et al. Knowledge and attitudes about human papillomavirus (HPV) and HPV vaccines amongwomen living in metropolitan and rural regions of China. Vaccine. 2009;27:1210–5.
Gao H, Okoror TA, Hyner GC. Focus group study of Chinese international Students’ knowledge and beliefs about HPV vaccination, before and after Reading an informational pamphlet about Gardasil(®). J Immigr Minor Health. 2016;18(5):1085–92.
Lee PW, Kwan TT, Tam KF, Chan KK, Young PM, Lo SS, et al. Beliefs about cervical cancer and human papillomavirus (HPV) and acceptability of HPV vaccination among Chinese women in Hong Kong. Prev Med. 2007;45(2–3):130–4.
Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, et al. Human papillomavirus vaccine introduction--the first five years. Vaccine. 2012;30(Suppl 5):F139–48.
Zhang Y, Wang Y, Liu L, Fan Y, Liu Z, Wang Y, et al. Awareness and knowledge about human papillomavirus vaccination and its acceptance in China: a meta-analysis of 58 observational studies. BMC Public Health. 2016;16:216.
Lee A, Ho M, Cheung CKM, Keung VMW. Factors influencing adolescent girls’ decision in initiation for HPV vaccination: a cross-sectional study in Hong Kong. BMC Public Health. 2014;14:925.
Gottvall M, Tyden T, Hoglund AT, Larsson M. Knowledge of human papillomavirus among high school students can be increased by an educational intervention. Int J STD AIDS. 2010;21(8):558–62.
Li J, Kang LN, Li B, Pang Y, Huang R, Qiao YL. Effect of a group educational intervention on rural Chinese women's knowledge and attitudes about human papillomavirus (HPV) and HPV vaccines. BMC Cancer. 2015;15:691.